IRONWOOD PHARMACEUTICALS INC Quarterly Costs and Expenses in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Ironwood Pharmaceuticals Inc quarterly/annual Costs and Expenses history and growth rate from Q1 2011 to Q3 2024.
  • Ironwood Pharmaceuticals Inc Costs and Expenses for the quarter ending September 30, 2024 was $66M, a 10.5% decline year-over-year.
  • Ironwood Pharmaceuticals Inc Costs and Expenses for the twelve months ending September 30, 2024 was $279M, a 79.3% decline year-over-year.
  • Ironwood Pharmaceuticals Inc annual Costs and Expenses for 2023 was $1.39B, a 766% increase from 2022.
  • Ironwood Pharmaceuticals Inc annual Costs and Expenses for 2022 was $160M, a 11.7% decline from 2021.
  • Ironwood Pharmaceuticals Inc annual Costs and Expenses for 2021 was $181M, a 26.4% decline from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $279M $66M -$7.76M -10.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $287M $69.4M -$1.12B -94.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $1.41B $63.9M +$19.9M +45.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $1.39B $80M +$41.1M +106% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-16
Q3 2023 $1.35B $73.7M +$33.6M +83.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $1.31B $1.19B +$1.15B +2763% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $165M $44M +$4.28M +10.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $160M $38.8M -$21.7M -35.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-16
Q3 2022 $182M $40.2M +$1.59M +4.12% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-16
Q2 2022 $180M $41.6M +$2.64M +6.79% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-16
Q1 2022 $178M $39.7M -$3.76M -8.66% Jan 1, 2022 Mar 31, 2022 10-K 2024-02-16
Q4 2021 $181M $60.5M -$4.76M -7.29% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-16
Q3 2021 $186M $38.6M -$19.3M -33.3% Jul 1, 2021 Sep 30, 2021 10-K 2023-02-16
Q2 2021 $206M $38.9M -$17.8M -31.4% Apr 1, 2021 Jun 30, 2021 10-K 2023-02-16
Q1 2021 $223M $43.4M -$23.3M -34.9% Jan 1, 2021 Mar 31, 2021 10-K 2023-02-16
Q4 2020 $247M $65.3M -$11.4M -14.9% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-18
Q3 2020 $258M $57.9M -$7.43M -11.4% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-18
Q2 2020 $265M $56.7M -$23.9M -29.7% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-18
Q1 2020 $289M $66.7M -$18.9M -22.1% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-18
Q4 2019 $308M $76.7M -$24.1M -23.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-17
Q3 2019 $332M $65.3M -$147M -69.2% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-17
Q2 2019 $479M $80.6M -$15.1M -15.8% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-17
Q1 2019 $495M $85.7M -$2.78M -3.14% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-17
Q4 2018 $497M $101M +$29.4M +41.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 $468M $212M +$106M +99.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 $362M $95.8M -$10.3M -9.71% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 $372M $88.4M -$3.43M -3.74% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 $376M $71.4M -$22.3M -23.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-25
Q3 2017 $398M $106M +$11.9M +12.6% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-25
Q2 2017 $386M $106M +$36.4M +52.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-25
Q1 2017 $350M $91.9M +$23.9M +35.1% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-25
Q4 2016 $326M $93.8M +$34.6M +58.6% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-22
Q3 2016 $291M $94.4M +$28.6M +43.5% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-22
Q2 2016 $263M $69.7M -$88K -0.13% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-22
Q1 2016 $263M $68M +$11M +19.3% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-22
Q4 2015 $252M $59.1M -$12.1M -16.9% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-22
Q3 2015 $264M $65.8M +$12.1M +22.6% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-22
Q2 2015 $252M $69.8M +$7.79M +12.6% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-22
Q1 2015 $244M $57M -$1.99M -3.38% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-22
Q4 2014 $246M $71.2M +$19.4M +37.5% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-19
Q3 2014 $226M $53.7M -$7.83M -12.7% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-19
Q2 2014 $234M $62M -$7.58M -10.9% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-19
Q1 2014 $242M $59M -$33.1M -35.9% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-19
Q4 2013 $275M $51.8M -$19.1M -27% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-18
Q3 2013 $294M $61.5M +$12.7M +26% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-18
Q2 2013 $281M $69.5M +$14.1M +25.4% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-18
Q1 2013 $267M $92.1M +$44.2M +92.3% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-18
Q4 2012 $223M $70.9M +$31.7M +80.9% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-07
Q3 2012 $191M $48.8M +$15M +44.2% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-07
Q2 2012 $176M $55.4M +$25.2M +83.5% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-07
Q1 2012 $151M $47.9M +$19.1M +66.4% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-07
Q4 2011 $132M $39.2M Oct 1, 2011 Dec 31, 2011 10-K 2013-02-21
Q3 2011 $33.8M Jul 1, 2011 Sep 30, 2011 10-K 2013-02-21
Q2 2011 $30.2M Apr 1, 2011 Jun 30, 2011 10-K 2013-02-21
Q1 2011 $28.8M Jan 1, 2011 Mar 31, 2011 10-K 2013-02-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.